Status: Recruiting
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
The purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology. The primary aim of this innovative immunotherapy using WT1/hTERT/Survivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of MDS patients.
Participants needed: 40
Trial details
Phase: Phase 1Age: 60+Biological sex: AllType: InterventionalSponsor: Affiliated Hospital to Academy of Military Medical SciencesUpdated: Aug 11, 2021Locations: 1
Eligibility criteria
elderly MDS patients; [+4]
serious infection was not controlled before treatment; [+2]